MaaT Pharma Presents Promising Preclinical Data at AACR for MaaT034 Aiming To Improve Patients’ Responses…
MaaT PharmaApril 8, 2024
MaaT Pharma Announces 2023 Annual Results and Provides a Business Overview The DSMB, based on…
MaaT PharmaMarch 28, 2024
MaaT Pharma Strengthens Executive Team Appointing Jonathan Chriqui as Chief Business Officer Lyon, France, March…
MaaT PharmaMarch 21, 2024
MaaT Pharma To Present New Preclinical Data at AACR for MaaT034 Aiming To Improve Patients’…
MaaT PharmaMarch 19, 2024
MaaT Pharma Announces Long Term Follow-Up Data for MaaT013 in Early Access Program to be…
MaaT PharmaMarch 12, 2024
MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the…
MaaT PharmaMarch 7, 2024
MaaT Pharma Releases its 2024 Financial Calendar Lyon, France, March 7, 2024 –6:00pm CET –…
MaaT PharmaMarch 7, 2024
MaaT Pharma indicates completion of Patient Recruitment for the Phase 2a Investigator-Sponsored Randomized Clinical Trial…
MaaT PharmaMarch 5, 2024
MaaT Pharma Announces Positive Review from the DSMB on the Ongoing Phase 1 Clinical Trial…
MaaT PharmaFebruary 29, 2024
